Drug · DIN 02249057
REPLAGAL
SINGLE-USE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 13, 2021; first marketed March 18, 2004.
- Drug Identification Number (DIN)
- 02249057
- Company (DIN owner)
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Schedule
- Prescription; Schedule D
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Agalsidase alfa A16AB03
- Class
- Human
- Record last updated
- August 7, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| AGALSIDASE ALFA | 1 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 19, 2021: NOC 25265New Drug Submission (NDS) · Transfer of drug identification number. labelling updates
- February 10, 2017: NOC 18950New Drug Submission (NDS)
- October 12, 2006: NOC 15722New Drug Submission (NDS) · Manufacturer name change
- February 6, 2004: NOC 3New Drug Submission (NDS)